Paul Moreton

1.3k total citations
21 papers, 872 citations indexed

About

Paul Moreton is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Paul Moreton has authored 21 papers receiving a total of 872 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Genetics, 15 papers in Pathology and Forensic Medicine and 10 papers in Immunology. Recurrent topics in Paul Moreton's work include Chronic Lymphocytic Leukemia Research (19 papers), Lymphoma Diagnosis and Treatment (15 papers) and Immunodeficiency and Autoimmune Disorders (10 papers). Paul Moreton is often cited by papers focused on Chronic Lymphocytic Leukemia Research (19 papers), Lymphoma Diagnosis and Treatment (15 papers) and Immunodeficiency and Autoimmune Disorders (10 papers). Paul Moreton collaborates with scholars based in United Kingdom, Sweden and Switzerland. Paul Moreton's co-authors include Peter Hillmen, Andy C. Rawstron, Ben Kennedy, Chris Fegan, David Oscier, Guy Lucas, Jane Tighe, M.J. Leach, Saad M. B. Rassam and Andrew Haynes and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Paul Moreton

21 papers receiving 850 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Paul Moreton United Kingdom 12 712 649 425 160 104 21 872
Myriam Mendila Germany 9 778 1.1× 752 1.2× 390 0.9× 163 1.0× 148 1.4× 16 947
Carmen D. Schweighofer Germany 15 840 1.2× 747 1.2× 394 0.9× 201 1.3× 120 1.2× 24 967
Alice Lynn United States 5 932 1.3× 674 1.0× 390 0.9× 281 1.8× 115 1.1× 8 990
Christian H. Geisler Denmark 19 779 1.1× 723 1.1× 449 1.1× 142 0.9× 278 2.7× 50 1.1k
Niki Stavroyianni Greece 18 448 0.6× 335 0.5× 298 0.7× 177 1.1× 222 2.1× 59 863
Nedjad Losic United States 10 547 0.8× 551 0.8× 304 0.7× 168 1.1× 284 2.7× 23 871
Anna‐Maria Fink Germany 17 886 1.2× 818 1.3× 364 0.9× 204 1.3× 183 1.8× 58 1.0k
Małgorzata Wach Poland 11 573 0.8× 448 0.7× 199 0.5× 221 1.4× 118 1.1× 35 695
Xavier C. Badoux United States 21 1.1k 1.6× 960 1.5× 456 1.1× 387 2.4× 250 2.4× 60 1.4k
Viktoria Hjalmar Sweden 8 326 0.5× 339 0.5× 238 0.6× 59 0.4× 122 1.2× 13 534

Countries citing papers authored by Paul Moreton

Since Specialization
Citations

This map shows the geographic impact of Paul Moreton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Moreton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Moreton more than expected).

Fields of papers citing papers by Paul Moreton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Moreton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Moreton. The network helps show where Paul Moreton may publish in the future.

Co-authorship network of co-authors of Paul Moreton

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Moreton. A scholar is included among the top collaborators of Paul Moreton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Moreton. Paul Moreton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kwok, Marwan, Andy C. Rawstron, Abraham Varghese, et al.. (2016). Minimal residual disease is an independent predictor for 10-year survival in CLL. Blood. 128(24). 2770–2773. 95 indexed citations
2.
Hillmen, Peter, John G. Gribben, George Follows, et al.. (2014). Rituximab Plus Chlorambucil As First-Line Treatment for Chronic Lymphocytic Leukemia: Final Analysis of an Open-Label Phase II Study. Journal of Clinical Oncology. 32(12). 1236–1241. 89 indexed citations
3.
Kwok, Marwan, Andy C. Rawstron, Abraham Varghese, et al.. (2014). Independent prognostic significance of minimal residual disease status in chronic lymphocytic leukaemia. The Lancet. 383. S66–S66. 4 indexed citations
4.
Burnett, Alan K., Nigel H. Russell, Mary Frances McMullin, et al.. (2012). A Randomised Comparison of Clofarabine Versus Low Dose Ara-C As First Line Treatment for Older Patients with AML. Blood. 120(21). 889–889. 8 indexed citations
5.
Hillmen, Peter, John G. Gribben, George Follows, et al.. (2010). Rituximab Plus Chlorambucil In Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukemia (CLL): Final Response Analysis of An Open-Label Phase II Study. Blood. 116(21). 697–697. 25 indexed citations
6.
Varghese, Abraham, Andy C. Rawstron, A. John Ashcroft, Paul Moreton, & Roger G. Owen. (2009). Assessment of Bone Marrow Response in Waldenström's Macroglobulinemia. Clinical Lymphoma & Myeloma. 9(1). 53–55. 28 indexed citations
7.
8.
Karlsson, Claes, Jeanette Lundin, Eva Kimby, et al.. (2008). Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced‐stage, relapsed chronic lymphocytic leukaemia. British Journal of Haematology. 144(1). 78–85. 23 indexed citations
9.
Bennett, Fiona, Andy C. Rawstron, Marieth Plummer, et al.. (2007). B‐cell chronic lymphocytic leukaemia cells show specific changes in membrane protein expression during different stages of cell cycle. British Journal of Haematology. 139(4). 600–604. 29 indexed citations
10.
11.
12.
Moreton, Paul, Ben Kennedy, Guy Lucas, et al.. (2005). Eradication of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia After Alemtuzumab Therapy Is Associated With Prolonged Survival. Journal of Clinical Oncology. 23(13). 2971–2979. 293 indexed citations
13.
14.
O’Connor, Sheila J.M., Kathryn Turner, Sharon Barrans, et al.. (2005). Bi-Allelic Deletion of 13q14 Is Associated with Inferior Progression Free Survival Compared to Mono-Allelic 13q14 Deletion in B-Cell Chronic Lymphocytic Leukaemia.. Blood. 106(11). 2936–2936. 1 indexed citations
15.
Moreton, Paul, Gareth J. Morgan, D. Gilson, et al.. (2004). The development of targeted chemotherapy for CNS lymphoma?a pilot study of the IDARAM regimen. Cancer Chemotherapy and Pharmacology. 53(4). 324–328. 14 indexed citations
16.
Moreton, Paul, Ben Kennedy, Andy C. Rawstron, & Peter Hillmen. (2004). The correlation between the eradication of minimal residual disease (MRD) following alemtuzumab for CLL and overall survival. Journal of Clinical Oncology. 22(14_suppl). 6566–6566. 2 indexed citations
17.
18.
Moreton, Paul, et al.. (2003). Achieving a MRD negative response after alemtuzumab for CLL is the best predictor for prolonged survival. Blood. 102(11). 39116. 5 indexed citations
19.
Moreton, Paul & Peter Hillmen. (2003). Alemtuzumab therapy in B-cell lymphoproliferative disorders. Seminars in Oncology. 30(4). 493–501. 31 indexed citations
20.
Rawstron, Andy C., Ben Kennedy, Paul Moreton, et al.. (2003). Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia. Blood. 103(6). 2027–2031. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Myriam Mendila Breakdown of academic impact, for papers by Carmen D. Schweighofer Breakdown of academic impact, for papers by Alice Lynn Breakdown of academic impact, for papers by Christian H. Geisler Breakdown of academic impact, for papers by Niki Stavroyianni Breakdown of academic impact, for papers by Nedjad Losic Breakdown of academic impact, for papers by Anna‐Maria Fink Breakdown of academic impact, for papers by Małgorzata Wach Breakdown of academic impact, for papers by Xavier C. Badoux Breakdown of academic impact, for papers by Viktoria Hjalmar
Rankless by CCL
2026